

OptimizeRx Corp  
Form 8-K  
November 14, 2012

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **November 14, 2012**

**OptimizeRx Corporation**

(Exact name of registrant as specified in its charter)

**Nevada**

**000-53605**

**26-1265381**

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

**400 Water Street, Suite 200, Rochester, MI 48307**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **248-651-6568**

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Edgar Filing: OptimizeRx Corp - Form 8-K

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1

## Section 2 - Financial Information

### Item 2.02 Results of Operations and Financial Condition.

We will hold a conference call to go over our financial results for the quarter and nine months ended September 30, 2012. The time and date of the call is scheduled for this Friday, November 16, 2012 at 12:00 PM (Noon) Eastern Standard Time.

Conference Call Dial-In Information:

Toll Free Dial-In Number (US & Canada): (888) 858-6021

US local toll Dial-In Number: (973) 935-2037

Conference code: 8856046544

The information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OptimizeRx Corporation**

/s/ David Lester

David Lester  
Chief Executive Officer

Date: November 14, 2012

